الفهرس | Only 14 pages are availabe for public view |
Abstract Pain and inflammation could have a negative impact on a patient’s quality of life and performance, causing them to sleep less. Dexketoprofen trometamol (DKT) is a water-soluble, nonselective NSAIDs. Because DKT is quickly eliminated in the urine after oral delivery, its efficacy is limited, and it must be taken repeatedly throughout the day. This study divided into two chapters that intended to formulate and characterize the potential of invasomes and transethasomes to enhance the transdermal transport of DKT to achieve an efficient anti-inflammatory and pain management. Chapter I: The deleterious effect of xylene-induced ear edema in rats: Protective role of dexketoprofen trometamol transdermal invasomes via inhibiting the oxidative stress/ NF-κB /COX-2 pathway. Chapter II: Transethosomes as breakthrough tool for controlled transdermal delivery of dexketoprofen trometamol: design, fabrication, statistical optimization, in-vitro, and ex vivo characterization. |